BioNexus Gene Lab Corp entered into ARC Group International Equity Purchase Agreement with ARC Group International Ltd. valued at up to $500,000,000 of common stock over 36 months (effective 2025-11-28).
“. On November 28, 2025, the Company entered into two (2) material definitive agreements described herein below. A. ARC Group International Equity Purchase Agreement On November 28, 2025, BioNexus Gene Lab Corp. (the “Company”) entered into an Equity Purchase Agreement (the “Purchase Agreement”) with ARC Group International Ltd. (“ARC”), the parent of ARC Group Securities, a FINRA registered broker/dealer. Under the terms of the Purchase Agreement, ARC has committed to purchase, from time to time at the Company’s discretion, up to $500,000,000 of the Company’s common stock, no par value per share (“Common Stock”), over a 36-month period (the “Facility”).”
Equity Issuances
BioNexus Gene Lab Corp issued 392,329 shares of common stock of common stock to Fidelion for issuance to Fidelion was made in reliance upon the exemption from registration under Section 4(a)(2) and Rule 506(b) of Regulation D.
“d and outstanding equity of Fidelion. The issuance to Fidelion was made in reliance upon the exemption from registration under Section 4(a)(2) and Rule 506(b) of Regulation D promulgated thereunder. Item 3.02 Unregistered Sales of Equity Securities. As described under Item 1.01 of this Current Report on Form 8-K,”
Equity Issuances
BioNexus Gene Lab Corp issued 175,000 shares of common stock of common stock to ARC for consideration for ARC’s commitment under the Purchase Agreement.
“the Company issued (i) 175,000 shares of common stock to ARC as consideration for ARC’s commitment under the Purchase Agreement”
Equity Issuances
BioNexus Gene Lab Corp issued restricted shares representing 19.9% of its outstanding common stock of common stock to Fidelion Diagnostics Pte. Ltd..
“In connection with the SSSA, upon completion the Company will issue restricted shares representing 19.9% of its outstanding common stock to Fidelion as consideration for the Company’s subscription of Fidelion shares.”
Su-Leng Tan Lee departed as acting Chief Financial Officer and Principal Financial Officer at BioNexus Gene Lab Corp.
“Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.”
Chong Set Fui (Angeline) was appointed as Chief Financial Officer and Principal Financial Officer at BioNexus Gene Lab Corp.
“On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.”
Listing & Compliance Notices
BioNexus Gene Lab Corp received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“April 30, 2025, BioNexus Gene Lab Corp. (the “Company”) received a formal notice from the Nasdaq Hearings Panel (the “Panel”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. The Company was previously notified of non-compliance with the Bid Price Rule and appeared before the Panel pursuant to Docket No. NQ 7050C-24. As of April 23, 2025, the Company’s common stock had maintained a closing bid price of $1.00 or greater for the requisite number of consecutive business day”
Governance Changes
BioNexus Gene Lab Corp: Amended articles of incorporation to effect a 1-for-10 reverse stock split (effective 2025-04-07).
“The Articles of Amendment regarding the reverse stock split was filed with the Wyoming Secretary of State on April 1, 2025”
Governance Changes
BioNexus Gene Lab Corp: Filed Articles of Amendment to authorize creation of Series Z Convertible Preferred Stock with special voting rights tied to a Reverse Stock Split proposal (effective 2025-02-11).
“On February 11, 2025, the Company filed with the Wyoming Secretary of State Articles of Amendment to its Articles of Incorporation (a true and correct copy of which is attached hereto as Exhibit 3.6) (“Amendment”). The Amendment authorizes the creation of one (1) share of the Series Z Convertible Preferred Stock.”
Listing & Compliance Notices
BioNexus Gene Lab Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“December 27, 2024, BioNexus Gene Lab Corp. (the “Company”) received a written notice from the Nasdaq Hearings Panel (the “Panel”) indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”). The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May”
Su-Leng Tan Lee was appointed as President at BioNexus Gene Lab Corp.
“Additionally, the Board has re-appointed Mr. Su-Leng Tan Lee as Secretary of the Company and has appointed him as President, effective immediately.”
Jook Yuen Low was appointed as Director at BioNexus Gene Lab Corp.
“On November 5, 2024, the Board of Directors of the Company appointed Ms. Jook Yuen Low as an independent director to the Board, effective immediately.”
Koon Wai Wong resigned as Director at BioNexus Gene Lab Corp.
“On October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of the Company, effective immediately.”
Wei Foong Lim resigned as Director at BioNexus Gene Lab Corp.
“On October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of the Company, effective immediately.”
Listing & Compliance Notices
BioNexus Gene Lab Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 8, 2024, the Company received notification from NASDAQ that, after an analysis of the requirements under Nasdaq Listing Rule 5810 (c)(3)(A), the Staff determined that the Company is eligible for an additional 180 calendar day extension period (the “ Additional Period ”), or until November 4, 2024. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event that the Company is not able to cure the bid price deficiency during the Additional”
Listing & Compliance Notices
BioNexus Gene Lab Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“November 6, 2023, BioNexus Gene Lab Corp. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (“Rule”) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Based on the closing bid price for the last 33 consecutive business days (including, in pa”
Wei Li Leong resigned as Chief Financial Officer at BioNexus Gene Lab Corp.
“On October 30, 2023, Ms. Wei Li Leong, the Chief Financial Officer (“CFO”), tendered her resignation letter to BioNexus Gene Lab Corp. (the “Company”) from her position at the Company.”
Chi Yuen Leong was appointed as Director at BioNexus Gene Lab Corp.
“On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. (“the Company”) approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023.”
Chi Yuen Leong was appointed as Chief Executive Officer at BioNexus Gene Lab Corp.
“On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. (“the Company”) approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023.”
Sook Keng Yeoh resigned as Chief Executive Officer at BioNexus Gene Lab Corp.
“On October 4, 2023, Mr. Sook Keng Yeoh, the Chief Executive Officer and a member of the Board of Directors, tendered his resignation letter to Bionexus Gene Lab Corp. (the “Company”) from his positions at the Company.”
Lee Su-Leng Tan was appointed as Chief Operating Officer at BioNexus Gene Lab Corp.
“the Board of Directors of the Company approved the appointment of Mr. Lee Su-Leng Tan as the Chief Operating Officer and not a director, effective September 1, 2023.”
Liong Tai Tan resigned as Director at BioNexus Gene Lab Corp.
“The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023.”
Liong Tai Tan resigned as Chief Operating Officer at BioNexus Gene Lab Corp.
“Mr. Liong Tai Tan, the Chief Operating Officer and a member of the Board of Directors, notified Bionexus Gene Lab Corp. (“the Company”) of his desire to resign from his position at the Company.”
Governance Changes
BioNexus Gene Lab Corp: Increased maximum number of directors from seven to nine (effective 2023-01-01).
“On July 21, 2013, the Board of Directors of the Company approved and ratified the Amended and Restated Bylaws (“Amended Bylaws”) of the Company to increase the maximum number of directors from seven (7) to nine (9), effective as of January 1, 2023.”
Material Agreements
BioNexus Gene Lab Corp entered into Underwriting Agreement with Network 1 Financial Securities, Inc. valued at total gross proceeds of $5.75 million (effective 2023-07-20).
“On July 20, 2023, BioNexus Gene Lab Corp. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Network 1 Financial Securities, Inc., as underwriter (the "Underwriter") pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the “Offering”) of 1,250,000 shares of common stock, priced at a public offering price of $4.00 per share. In addition, pursuant to the Underwriting Agreement, the Underwriter was granted a 45-day option (the “Over-Allotment Option") to purchase up to an additional 187,500 shares of common stock at the public offering price of $4.00 per share. The Underwriter fully exercised the Over-Allotment Option on July 24, 2023. The securities were offered by the Company pursuant to the registration statement on Form S-1 (File No. 333-269753), which was originally filed with the U.S. Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as a”
Governance Changes
BioNexus Gene Lab Corp: Reverse stock split (1-for-12) effected by filing an Article of Amendment to the Articles of Incorporation (effective 2023-07-19).
“On July 19, 2023, the Financial Industry Regulatory Authority announced the Revised Reverse Stock Split. On July 20, 2023, the Revised Reverse Stock Split went effective.”
Yee Meng Wong was appointed as President at BioNexus Gene Lab Corp.
“On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as the Chief Executive Officer and director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022.”
Sook Keng Yeoh was appointed as Chief Executive Officer at BioNexus Gene Lab Corp.
“On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as the Chief Executive Officer and director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022.”
Yeat Min Fong was appointed as Chairman at BioNexus Gene Lab Corp.
“On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as the Chief Executive Officer and director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022.”
Chi Yuen Leong resigned as President at BioNexus Gene Lab Corp.
“On August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified Bionexus Gene Lab Corp (“the Company”) their desire to resign from their positions at the Company.”
Chan Chong Wong resigned as Chief Executive Officer at BioNexus Gene Lab Corp.
“On August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified Bionexus Gene Lab Corp (“the Company”) their desire to resign from their positions at the Company.”
Soo Kow Lai resigned as Chairman at BioNexus Gene Lab Corp.
“On August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified Bionexus Gene Lab Corp (“the Company”) their desire to resign from their positions at the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.